Altimmune (MEX:ALT1) Cyclically Adjusted PS Ratio: (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ALT1 Altimmune Inc MEX:ALT1
28 GF Score
Price MXN48.50
! 2 Warning Signs
View Full Analysis

What is Altimmune Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Altimmune  (MEX:ALT1) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Altimmune Cyclically Adjusted PS Ratio Related Terms


Altimmune Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Altimmune's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altimmune Cyclically Adjusted PS Ratio Chart

Altimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 0.50 0.56 0.00 0.00

Altimmune Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEX:ALT1 vs VSTM, PRME, RLMD: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Altimmune's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Altimmune Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altimmune's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Altimmune's Cyclically Adjusted PS Ratio falls into.


MEX:ALT1
28GF Score
Altimmune Inc MEX:ALT1
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Altimmune Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Altimmune's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Altimmune's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Altimmune Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 12.704 241.018 17.405
201609 0.422 241.428 0.577
201612 21.691 241.432 29.667
201703 0.407 243.801 0.551
201706 0.221 244.955 0.298
201709 0.946 246.819 1.266
201712 370.039 246.524 495.658
201803 72.214 249.554 95.554
201806 49.679 251.989 65.101
201809 37.297 252.439 48.788
201812 5.600 251.233 7.360
201903 6.042 254.202 7.849
201906 2.379 256.143 3.067
201909 0.861 256.759 1.107
201912 0.722 256.974 0.928
202003 3.434 258.115 4.393
202006 0.932 257.797 1.194
202009 1.963 260.280 2.490
202012 1.265 260.474 1.604
202103 0.440 264.877 0.549
202106 0.066 271.696 0.080
202109 0.079 274.310 0.095
202112 1.578 278.802 1.869
202203 0.014 287.504 0.016
202206 0.003 296.311 0.003
202209 0.001 296.808 0.001
202212 -0.043 296.797 -0.048
202303 0.008 301.836 0.009
202306 0.002 305.109 0.002
202309 0.118 307.789 0.127
202312 0.011 306.746 0.012
202403 0.001 312.332 0.001
202406 0.001 314.175 0.001
202409 0.001 315.301 0.001
202412 0.001 315.605 0.001
202503 0.001 319.799 0.001
202506 0.001 322.561 0.001
202509 0.001 324.800 0.001
202512 0.004 324.054 0.004
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Altimmune Business Description

Other Exchanges ALT:USA0A4C:UK3G0:Germany
Address 910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
28GF Score

Get the complete analysis for MEX:ALT1

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN48.50
Price